Norges Bank Morphic Holding, Inc. Transaction History

Norges Bank

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$21.33 - $59.42 $925,721 - $2.58 Million	-43,400 Closed	0 $0
Q4 2022 Feb 14, 2023	BUY	$24.14 - $30.37 $1.01 Million - $1.28 Million	42,000 New	42,000 $1.12 Million
Q3 2022 Nov 13, 2023	BUY	$22.23 - $33.37 $964,782 - $1.45 Million	43,400 New	43,400 $1.23 Million
Q2 2021 Aug 10, 2021	SELL	$45.13 - $64.99 $3.7 Million - $5.32 Million	-81,900 Closed	0 $0
Q1 2021 May 09, 2022	BUY	$29.77 - $84.85 $2.44 Million - $6.95 Million	81,900 New	81,900 $5.18 Million

4.7M

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.